Habitat Imaging-Based 18F-FDG PET/CT Radiomics for the Preoperative Discrimination of Non-small Cell Lung Cancer and Benign Inflammatory Diseases

Chen, Ling; Liu, Kanfeng; Zhao, Xin; Shen, Hui; Zhao, Kui; Zhu, Wentao

doi:10.3389/fonc.2021.759897

Cited by 10 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PET radiomics in pulmonary oncology gathered 107 articles [ 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 ,…”

Section: Resultsunclassified

Radiomics in Oncological PET Imaging: A Systematic Review—Part 1, Supradiaphragmatic Cancers

et al. 2022

View full text Add to dashboard Cite

Radiomics is an upcoming field in nuclear oncology, both promising and technically challenging. To summarize the already undertaken work on supradiaphragmatic neoplasia and assess its quality, we performed a literature search in the PubMed database up to 18 February 2022. Inclusion criteria were: studies based on human data; at least one specified tumor type; supradiaphragmatic malignancy; performing radiomics on PET imaging. Exclusion criteria were: studies only based on phantom or animal data; technical articles without a clinically oriented question; fewer than 30 patients in the training cohort. A review database containing PMID, year of publication, cancer type, and quality criteria (number of patients, retrospective or prospective nature, independent validation cohort) was constructed. A total of 220 studies met the inclusion criteria. Among them, 119 (54.1%) studies included more than 100 patients, 21 studies (9.5%) were based on prospectively acquired data, and 91 (41.4%) used an independent validation set. Most studies focused on prognostic and treatment response objectives. Because the textural parameters and methods employed are very different from one article to another, it is complicated to aggregate and compare articles. New contributions and radiomics guidelines tend to help improving quality of the reported studies over the years.

show abstract

Section: Resultsunclassified

Radiomics in Oncological PET Imaging: A Systematic Review—Part 1, Supradiaphragmatic Cancers

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Previous studies ( 28 , 29 ) inferred that radiomics signatures make a remarkable impact on distinguishing lung cancer from inflammatory lesions. We demonstrated the value of quantitative radiomics features for differentiating PTMA from LP.…”

Section: Discussionmentioning

confidence: 98%

Combined model of radiomics and clinical features for differentiating pneumonic-type mucinous adenocarcinoma from lobar pneumonia: An exploratory study

Liu

Chen

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

PurposeThe purpose of this study was to distinguish pneumonic-type mucinous adenocarcinoma (PTMA) from lobar pneumonia (LP) by pre-treatment CT radiological and clinical or radiological parameters.MethodsA total of 199 patients (patients diagnosed with LP = 138, patients diagnosed with PTMA = 61) were retrospectively evaluated and assigned to either the training cohort (n = 140) or the validation cohort (n = 59). Radiomics features were extracted from chest CT plain images. Multivariate logistic regression analysis was conducted to develop a radiomics model and a nomogram model, and their clinical utility was assessed. The performance of the constructed models was assessed with the receiver operating characteristic (ROC) curve and the area under the curve (AUC). The clinical application value of the models was comprehensively evaluated using decision curve analysis (DCA).ResultsThe radiomics signature, consisting of 14 selected radiomics features, showed excellent performance in distinguishing between PTMA and LP, with an AUC of 0.90 (95% CI, 0.83–0.96) in the training cohort and 0.88 (95% CI, 0.79–0.97) in the validation cohort. A nomogram model was developed based on the radiomics signature and clinical features. It had a powerful discriminative ability, with the highest AUC values of 0.94 (95% CI, 0.90–0.98) and 0.91 (95% CI, 0.84–0.99) in the training cohort and validation cohort, respectively, which were significantly superior to the clinical model alone. There were no significant differences in calibration curves from Hosmer–Lemeshow tests between training and validation cohorts (p = 0.183 and p = 0.218), which indicated the good performance of the nomogram model. DCA indicated that the nomogram model exhibited better performance than the clinical model.ConclusionsThe nomogram model based on radiomics signatures of CT images and clinical risk factors could help to differentiate PTMA from LP, which can provide appropriate therapy decision support for clinicians, especially in situations where differential diagnosis is difficult.

show abstract

“…To preoperatively discriminate between non-small cell lung cancer and benign inflammatory diseases, PET/CT was separated into variant subregions based on the adapted clustering method. The AUC of the subregion-based PET/CT radiomics models was 0.7270 ± 0.0147, which showed a significantly improved discrimination performance compared to conventional methods (p <.001) 69 . Radiomic features were extracted from whole PET, CT, and subregions to estimate the prognosis of patients with locally advanced cervical cancer treated with chemoradiotherapy.…”

Section: Progress Of Radiomicsmentioning

confidence: 88%

The progress of multimodal imaging combination and subregion based radiomics research of cancers

Zhang¹,

Wang²,

Peng³

et al. 2022

Int. J. Biol. Sci.

View full text Add to dashboard Cite

In recent years, with the standardization of radiomics methods; development of tools; and popularization of the concept, radiomics has been widely used in all aspects of tumor diagnosis; treatment; and prognosis. As the study of radiomics in cancer has become more advanced, the currently used methods have revealed their shortcomings. The performance of cancer radiomics based on single-modality medical images, which based on their imaging principles, only partially reflects tumor information, has been necessarily compromised. Using the whole tumor as a region of interest to extract radiomic features inevitably leads to the loss of intra-tumoral heterogeneity of, which also affects the performance of radiomics. Radiomics of multimodal images extracts various aspects of information from images of each modality and then integrates them together for model construction; thus, avoiding missing information. Subregional segmentation based on multimodal medical image combinations allows radiomics features acquired from subregions to retain tumor heterogeneity, further improving the performance of radiomics. In this review, we provide a detailed summary of the current research on the radiomics of multimodal images of cancer and tumor subregion-based radiomics, and then raised some of the research problems and also provide a thorough discussion on these issues.

show abstract

Habitat Imaging-Based 18F-FDG PET/CT Radiomics for the Preoperative Discrimination of Non-small Cell Lung Cancer and Benign Inflammatory Diseases

Cited by 10 publications

References 42 publications

Radiomics in Oncological PET Imaging: A Systematic Review—Part 1, Supradiaphragmatic Cancers

Radiomics in Oncological PET Imaging: A Systematic Review—Part 1, Supradiaphragmatic Cancers

Combined model of radiomics and clinical features for differentiating pneumonic-type mucinous adenocarcinoma from lobar pneumonia: An exploratory study

The progress of multimodal imaging combination and subregion based radiomics research of cancers

Contact Info

Product

Resources

About